Corindus Vascular Robotics trades as part of the healthcare sector and medical devices industry. The company CEO is Mark J. Toland. Corindus Vascular Robotics Inc is engaged in the design, manufacture, and sale of precision vascular robotic-assisted systems for use in interventional vascular procedures the CorPath System. Its product includes the CorPath 200 and CorPath GRX Systems.
Previous Intraday Trading Performance:
The CVRS stock showed a previous change of 8.33% with an open at 1.47 and a close of 1.56. It reached an intraday high of 1.58 and a low of 1.40.
SeekingAlpha: More on Corindus Vascular Robotics Q4 results
The stock has a market cap of $315.4m with 202.2m shares outstanding, of which the float is 201.4m shares. Trading volume reached 1,852,768 shares compared to its average volume of 609,119 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.
Historical Trading Performance:
Over the last five trading days, Corindus Vascular Robotics shares returned 14.71% and in the past 30 trading days it returned 33.33%. Over three months, it changed 24.80%. In one year it has changed 14.71% and within that year its 52-week high was 1.65 and its 52-week low was 0.70. CVRS stock is 122.83% above its 52 Week Low.
Our calculations show a 200 day moving average of 1.12 and a 50 day moving average of 1.24. Currently CVRS stock is trading 39.07% above its 200 day moving average.
The last annual fiscal EPS for the company was reported at -0.2 that ended on 31st of December 2017. The TTM EPS is 0.00, which comes to a TTM PE of 0.00.
The following are the last four quarter reported earnings per share:
09-30-2017: -0.05 (estimated)
Indicators to Watch:
Based on the latest filings, there is 37.60% of institutional ownership. Short-interest is 12,833,085, which is 6.35% of shares outstanding. The short-interest ratio or days-to-cover ratio is 30.07. This stock has a moderate level of short interest, but may still be a buying opportunity depending on other indicators.
The current calculated beta is 1.84
Based on last reported financials, the company’s return on equity is -386.98%, return on assets is -122.46%, price-to-sales is 47.67 and price-to-book is 85.24.
All scores are out of six:
0 :Valuation Score
0 :Past Performance Score
2 :Financial Strength Score
2 :Future Growth Score
0 :Dividend Score
1 :Overall Score